L Herrera

Research Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain; Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.

Identifying SARS-CoV-2 'memory' NK cells from COVID-19 convalescent donors for adoptive cell therapy (RELEASE)

S Perez-Lopez

Cell Therapy and Regenerative Medicine Unit. Hematology and Hemotherapy Department. Central University Hospital of Asturias (HUCA). Health Research Institute of Asturias (ISPA). Oviedo. 33011

Treatment of chronic limb threatening ischemia (CLTI) with autologous bone marrow-mononuclear cells: preliminary results of a clinical trial of an advanced therapy medicinal product

I Romayor

BioCruces/Hospital Universitario Cruces; Centro Vasco de Transfusión y Tejidos Humanos (CVTTH)

Correcting APDS2 syndrome-caused mutation for future gene and cell therapies

A Hinckley Boned

UGR; Lentistem

New regulatory region in WAS intron 1 involved in megakaryocytic differentiation

M Rojas-Torres 

Universidad de Cádiz; Instituto de innovación e investigación biomédica de Cádiz

Bio-distribution evaluation of endothelial colony forming cells in a murine model of chronic limb-threating ischemia

J Cerón

Universidad de Granada; GENyO- Centro de Genomica e Investigacion Oncologica: Pfizer / Universidad de Granada / Junta de Andalucia

Genetic rescue of a human model of Bernard-Soulier syndrome based on CRISPR-Cas9 gene therapy

C Pérez-García

Instituto de Neurociencias - UMH; Universidad Católica de Murcia- UCAM

Novel in vitro approaches to study X-linked adrenoleukodystrophy

D Herrero

Centro de Investigacion Medica Aplicada (CIMA); Universidad Francisco de Vitoria

Substrate Reduction Therapy for Primary Hyperoxaluria type I based on CasRx mediated GO mRNA cleavage

M Lopez-Santalla

Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Centre for Biomedical Network Research on Rare Diseases (CIBER-ER) and Advanced Therapy Unit, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.

CCR2 expression is not necessary for the beneficial effects of mesenchymal/stromal cell-based therapy in DSS-induced colitis

M Lopez-Santalla

Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT) and Centre for Biomedical Network Research on Rare Diseases (CIBER-ER); Advanced Therapy Unit, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.

Mesenchymal stem/stromal cell-based therapy fails to provide clinical benefit in K/BxN serum transfer-induced arthritis

M Lopez-Santalla

Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Centre for Biomedical Network Research on Rare Diseases (CIBER-ER) and Advanced Therapy Unit, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.

Enhanced therapeutic effect of mesenchymal stem/stromal cells overexpressing CXCR4 and IL10 in experimental colitis

A Hejmowski

Pall Life Sciences

Empty and Full Separation of Adeno-Associated Virus Vectors by Anion Exchange Membrane Chromatography